$2.52
5.62% today
Nasdaq, Apr 03, 03:45 pm CET
ISIN
US50015M1099
Symbol
KOD
Sector
Industry

Kodiak Sciences, Inc. Stock price

$2.67
-1.23 31.54% 1M
+0.05 1.91% 6M
-7.28 73.17% YTD
-1.66 38.34% 1Y
-5.23 66.20% 3Y
-41.05 93.89% 5Y
-7.49 73.72% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.11 4.30%
ISIN
US50015M1099
Symbol
KOD
Sector
Industry

Key metrics

Market capitalization $140.84m
Enterprise Value $143.12m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.93
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-186.85m
Free Cash Flow (TTM) Free Cash Flow $-117.72m
Cash position $168.07m
EPS (TTM) EPS $-3.35
P/E forward negative
Short interest 8.21%
Show more

Is Kodiak Sciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Kodiak Sciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Kodiak Sciences, Inc. forecast:

1x Buy
25%
1x Hold
25%
2x Sell
50%

Analyst Opinions

4 Analysts have issued a Kodiak Sciences, Inc. forecast:

Buy
25%
Hold
25%
Sell
50%

Financial data from Kodiak Sciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 27 27
3% 3%
-
-27 -27
3% 3%
-
- Selling and Administrative Expenses 7.34 7.34
62% 62%
-
- Research and Development Expense 126 126
39% 39%
-
-160 -160
36% 36%
-
- Depreciation and Amortization 27 27
3% 3%
-
EBIT (Operating Income) EBIT -187 -187
33% 33%
-
Net Profit -176 -176
32% 32%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kodiak Sciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kodiak Sciences, Inc. Stock News

Neutral
PRNewsWire
7 days ago
PALO ALTO, Calif. , March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024.
Neutral
PRNewsWire
24 days ago
Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significance PALO ALTO, Calif.
Positive
Seeking Alpha
about one month ago
Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD's pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028. The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027.
More Kodiak Sciences, Inc. News

Company Profile

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Head office United States
CEO Victor Perlroth
Employees 109
Founded 2009
Website www.kodiak.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today